The nation of Zimbabwe has rejected a substantial US health deal worth 367 million US dollars (£272m) spanning five years because of Washington's request for confidential information.
The decision became public following a official document dated December was leaked, indicating that Head of State Emmerson Mnangagwa felt the arrangement was "lopsided".
A government spokesperson later clarified that the United States was requesting biological samples for research and commercial purposes while refused to share the resulting advantages from any future treatments.
"We must now begin the challenging and unfortunate task of ending our health aid in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy noted the US had provided more than $1.9bn in health funding to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has appealed for further dialogue to secure a deal acceptable to all parties so the nation's critical HIV treatment initiative can be sustained.
Wider Context
This development follows a comparable situation in neighbouring Kenya, where a high court halted a similar health funding agreement after concerns were raised about the safety of Kenyans' health data.
Since returning to office last year, US President Donald Trump has slashed foreign aid and closed the US Agency for International Development (USAID).
USAID had overseen assistance for the American government, but Trump stated its expenditure was "wasteful" and his government was pursuing government-to-government agreements to enhance transparency and accountability.
Based on reports, Sixteen nations in Africa have to date agreed to these new health pacts, constituting more than $18.3bn in new funding.
Details of the Rejected Deal
The money for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this collaboration might have yielded significant advantages for the people of Zimbabwe, especially the 1.2 million currently on antiretroviral therapy via American-funded programmes," Tremont added.
However, official spokesman Nick Mangwana maintained the arrangement was "asymmetrical".
"The proposal required Zimbabwe to share its biological resources and data for a long time, with no corresponding promise of access to any scientific breakthroughs – such as new medicines or tests – that could be developed from that shared data," he stated.
"Put simply, our country would supply the raw materials for scientific discovery with no certainty that the resulting innovations would be accessible to our citizens if a future health crisis emerge."
Sovereignty and International Frameworks
Mangwana further noted that the US's withdrawal from the World Health Organization (WHO) and its push of one-on-one deals were disrupting frameworks previously established via the international health agency.
Mangwana cited its Pathogen Access and Benefit Sharing system created to manage potential global health emergencies.
"This framework is intended to ensure that when a nation provides its samples, the resulting advantages – such as vaccines and treatments – are shared equitably, not monopolised solely by those with the capability to develop them."
The government's concerns regarding the US deal "should not be misconstrued as hostility towards the US," Mangwana stressed.
"We are open to ongoing dialogue with our American counterparts on how subsequent co-operation could be designed in a way that honours the sovereignty and interests of both nations."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it recognised the official position, but recommended that negotiations need to persist considering much of the country's Aids initiatives relied on external financing.
"Where technical issues exist, including those relating to information security or agreement terms, these can frequently be resolved through technical clarification and mutually agreed protections," it added.
The halted deal underscores the ongoing debate between accepting vital foreign assistance and safeguarding national sovereignty in an ever more data-driven world.